- Home
- CISS vs GLMD Comparison
CISS vs GLMD Comparison
Compare CISS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- GLMD
- Stock Information
- Founded
- CISS 2022
- GLMD 2000
- Country
- CISS Greece
- GLMD Israel
- Employees
- CISS N/A
- GLMD N/A
- Industry
- CISS Marine Transportation
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- GLMD Health Care
- Exchange
- CISS Nasdaq
- GLMD Nasdaq
- Market Cap
- CISS 4.7M
- GLMD 4.5M
- IPO Year
- CISS N/A
- GLMD 2014
- Fundamental
- Price
- CISS $1.02
- GLMD $2.70
- Analyst Decision
- CISS
- GLMD
- Analyst Count
- CISS 0
- GLMD 0
- Target Price
- CISS N/A
- GLMD N/A
- AVG Volume (30 Days)
- CISS 81.4K
- GLMD 21.6K
- Earning Date
- CISS 03-25-2025
- GLMD 04-03-2025
- Dividend Yield
- CISS N/A
- GLMD N/A
- EPS Growth
- CISS N/A
- GLMD N/A
- EPS
- CISS N/A
- GLMD N/A
- Revenue
- CISS $46,661,732.00
- GLMD N/A
- Revenue This Year
- CISS N/A
- GLMD N/A
- Revenue Next Year
- CISS N/A
- GLMD N/A
- P/E Ratio
- CISS N/A
- GLMD N/A
- Revenue Growth
- CISS 491.48
- GLMD N/A
- 52 Week Low
- CISS $0.90
- GLMD $2.24
- 52 Week High
- CISS $29.75
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- CISS 32.70
- GLMD 49.41
- Support Level
- CISS $1.15
- GLMD $2.24
- Resistance Level
- CISS $1.21
- GLMD $2.72
- Average True Range (ATR)
- CISS 0.08
- GLMD 0.20
- MACD
- CISS 0.00
- GLMD 0.02
- Stochastic Oscillator
- CISS 32.43
- GLMD 71.47
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.